Results 91 to 100 of about 1,231 (164)

Aerodynamic engineering of a pulmonary prime-pull vaccine against Tuberculosis [PDF]

, 2018
Tuberculosis (TB) remains the infectious disease with the highest mortality alongside HIV. Despite the existence of the Bacillus Calmette-Guerin (BCG) vaccine there is an unmet need for an effective vaccine against pulmonary TB, the most common form of ...
Roces Rodriguez, Carla Belen.
core   +2 more sources

High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis

Frontiers in Immunology, 2018
Mycobacterium tuberculosis (Mtb), the etiologic agent of tuberculosis (TB), causes 1.8M deaths annually. The current vaccine, BCG, has failed to eradicate TB leaving 25% of the world’s population with latent Mtb infection (LTBI), and 5–10% of these ...
Rolf Billeskov, Thomas Lindenstrøm, Joshua Woodworth, Cristina Vilaplana, Pere-Joan Cardona, Joseph P. Cassidy, Rasmus Mortensen, Else Marie Agger, Peter Andersen   +8 more
doaj   +1 more source

New approaches to the development of liposomal viral vaccines [PDF]

, 2014
Ліпосомальні технології доставки вакцини в даний час переживають своє нове відродження. Ліпосоми (везикули з фосфоліпідного бішару) є універсальними і надійними системами доставки антигенів для індукції антитіл і Т- лімфоцитів.
Волянський, А.Ю., Давидова, Т.В.   +1 more
core  

COMBINATORIAL ADMINISTRATION OF SYNTHETIC TLR4 AGONIST INI-2002 AND NOVEL MINCLE AGONIST UM-1098 DELIVERED VIA A-SNPS RESULTS IN SYNERGISTIC IL-1β PRODUCTION IN HUMAN PRIMARY CELLS AND ENHANCES TH1 AND TH17 RESPONSES IN VIVO [PDF]

, 2022
Tuberculosis (TB) kills more people each year than any infectious disease worldwide with recent exception of SARS-CoV-2. Though the Bacille Calmette Guerin (BCG) vaccine confers protection against severe extrapulmonary forms of TB, there is no licensed ...
Buhl, Cassandra, Jones, Grace D, Riel, Asia Marie Stephanie, Riffey, Alexander   +3 more
core   +1 more source

Lactobacillus plantarum producing a Chlamydia trachomatis antigen induces a specific IgA response after mucosal booster immunization.

PLoS ONE, 2017
Mucosal immunity is important for the protection against a wide variety of pathogens. Traditional vaccines administered via parenteral routes induce strong systemic immunity, but they often fail to generate mucosal IgA.
Katarzyna Kuczkowska, Ine Myrbråten, Lise Øverland, Vincent G H Eijsink, Frank Follmann, Geir Mathiesen, Jes Dietrich   +6 more
doaj   +1 more source

An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial [PDF]

Background There is no vaccine against the major global pathogen Chlamydia trachomatis; its different serovars cause trachoma in the eye or chlamydia in the genital tract.
Amini, Fahimah, Andersen, Peter L, Bang, Peter, Borges, Álvaro H, Cheeseman, Hannah M, Cole, Tom, Day, Suzanne, Dietrich, Jes, Dohn, Rebecca B, Evans, Abbey, Follmann, Frank, Jensen, Charlotte G, Joypooranachandran, Jennifer, Kristiansen, Max P, Lemm, Nana-Marie, McFarlane, Leon R, Olsen, Anja W, Pollock, Katrina M, Rosenkrands, Ida, Schmidt, Kirstine L, Schronce, Joanna, Shattock, Robin J, Skallerup, Per, Søndergaard, Rie E   +23 more
core   +2 more sources

Liposome-based cationic adjuvant CAF01 enhances the protection conferred by a commercial inactivated influenza vaccine in ferrets

, 2009
Objectives: To assess the effect of CAF01 adjuvant associated to a commercial trivalent inactivated influenza vaccine in the ferret model. Methods:  Ferrets were vaccinated with a range of doses of Sanofi-Pasteur's Vaxigrip with or without the CAF01 adjuvant, and challenged with either one of two H1N1 influenza A virus strains.
Martel, Cyril Jean-Marie, Agger, Else Marie, Jensen, Trine Hammer, Nielsen, Lars Peter, Blixenkrone-Møller, Merete, Andersen, Peter, Aasted, Bent   +6 more
openaire   +1 more source

Phosphatidylinositolmannoside vaccination induces lipid-specific Th1-responses and partially protects guinea pigs from Mycobacterium tuberculosis challenge. [PDF]

Sci Rep, 2023
Eckhardt E, Schinköthe J, Gischke M, Sehl-Ewert J, Corleis B, Dorhoi A, Teifke J, Albrecht D, Geluk A, Gilleron M, Bastian M.   +10 more
europepmc   +1 more source

Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi.

Parasitology, 2016
The CAF01 adjuvant has previously been shown to be safe for human use and to be a potent adjuvant for several vaccine antigens. In the present work, we sought to optimize the Leishmania amazonensis antigens (LaAg) intranasal vaccine in an attempt to enhance the protective immune responses against Leishmania (infantum) chagasi by using the CAF01 ...
Janine Miranda, Leal, Marcelle, Mosquini, Luciana Polaco, Covre, Nataly Pescinalli, Stagmiller, Rodrigo Ribeiro, Rodrigues, Dennis, Christensen, Herbert Leonel, de Matos Guedes, Herbert Leonel De Matos, Guedes, Bartira, Rossi-Bergmann, Daniel Cláudio De Oliviera, Gomes   +9 more
openaire   +1 more source

Head-to-Head Comparison of Novel Vaccine Technologies Comes with a Minefield of Challenges. [PDF]

Pharmaceutics, 2023
Christensen D.
europepmc   +1 more source